Finlay MacKenzie
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Finlay MacKenzie has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Rachel Marrington
Birmingham Quality (UK NEQAS) , 1732 University Hospitals Birmingham NHS Foundation Trust , Birmingham , UK
9 shared publications - Annette Thomas
Weqas, Cardiff & Vale University Health Board, Cardiff, UK
3 shared publications Danielle Freedman
Clinical Biochemistry, Luton & Dunstable University Hospital NHS Foundation Trust (Bedfordshire Hospitals NHS Foundation Trust), Luton, UK
3 shared publications- David Housley
Clinical Biochemistry, Luton & Dunstable University Hospital NHS Foundation Trust (Bedfordshire Hospitals NHS Foundation Trust), Luton, UK
3 shared publications - Martin Myers
GIRFT Pathology, NHS England, London, UK
3 shared publications Gareth Davies
Weqas, Cardiff and Vale University Health Board , Cardiff , UK
2 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by Becaris Publishing Limited in Journal of Patient Centricity
- Vol. 1 (2)
The Yellow Card Scheme for laboratory medicine in vitro diagnostics
Background: The Yellow Card Scheme was introduced in the UK in 1964 with an aim to address adverse drug reactions patient safety concerns. Medical devices are now included within the scope of reportable events. Aim: We report here what we believe is the first survey of the Yellow Card Scheme in relation to medical devices in the clinical laboratory. Materials & methods: A Microsoft Forms descriptive, cross-sectional survey was made available by the Patient Focused Laboratory Medicine Group to anyone working within the discipline of laboratory medicine in the UK; however, dissemination was limited through primarily clinical biochemistry channels. The survey was open for 32 days. Questions were structured that respondents could only continue, firstly if they were aware of the Yellow Card Scheme and a secondly, if they had ever made a submission. We know from external quality assessment post-market surveillance that over the last year there have been multiple assays with significant changes in analytical performance to cause a change in patient management, therefore it would be expected that a notable number of Yellow Cards should be reported. Results: Responses were received from 321 individuals. Out of the 207 respondents who were aware of the Yellow Card Scheme, 140 (68%) have not raised a Yellow Card. Of the Yellow Cards that had been raised, only 23% of respondents who have raised a Yellow Card use the Scheme regularly, this equates to only 5% of the total respondents to the survey. Free text comments were allowed to some questions, a few responses are included in full in the paper, some of which are alarming. Conclusion: Lack of awareness of the overall process shows that there is an educational issue and concerns about completion of the form, lack of feedback and consequential disengagement with the process potentially means it is not fit for purpose, which could explain why people are not using it. We believe that this is a potentially huge patient safety issue.
- 1 October 2026
- Published by Becaris Publishing Limited in Journal of Patient Centricity
- Vol. 1 (2)
Open AccessThe Yellow Card Scheme for laboratory medicine in vitro diagnostics
Background: The Yellow Card Scheme was introduced in the UK in 1964 with an aim to address adverse drug reactions patient safety concerns. Medical devices are now included within the scope of reportable events. Aim: We report here what we believe is the first survey of the Yellow Card Scheme in relation to medical devices in the clinical laboratory. Materials & methods: A Microsoft Forms descriptive, cross-sectional survey was made available by the Patient Focused Laboratory Medicine Group to anyone working within the discipline of laboratory medicine in the UK; however, dissemination was limited through primarily clinical biochemistry channels. The survey was open for 32 days. Questions were structured that respondents could only continue, firstly if they were aware of the Yellow Card Scheme and a secondly, if they had ever made a submission. We know from external quality assessment post-market surveillance that over the last year there have been multiple assays with significant changes in analytical performance to cause a change in patient management, therefore it would be expected that a notable number of Yellow Cards should be reported. Results: Responses were received from 321 individuals. Out of the 207 respondents who were aware of the Yellow Card Scheme, 140 (68%) have not raised a Yellow Card. Of the Yellow Cards that had been raised, only 23% of respondents who have raised a Yellow Card use the Scheme regularly, this equates to only 5% of the total respondents to the survey. Free text comments were allowed to some questions, a few responses are included in full in the paper, some of which are alarming. Conclusion: Lack of awareness of the overall process shows that there is an educational issue and concerns about completion of the form, lack of feedback and consequential disengagement with the process potentially means it is not fit for purpose, which could explain why people are not using it. We believe that this is a potentially huge patient safety issue.
- 14 August 2026
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
Two CCLM papers: different routes, common goals
- 14 August 2026
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
Two CCLM papers: different routes, common goals
- 24 June 2026
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 64 (11) , 2389-2397
Unwarranted variation in total B12 test thresholds for the diagnosis of vitamin B12 deficiency across the UK and the validation of a method-specific total B12 reference interval for the Beckman Coulter DxI platform to support implementation of NICE NG239
Background: Prompt diagnosis and treatment of vitamin B12 deficiency prevents haematological, neurological, psychological and psychiatric disturbances. During November 2024, reference interval data used for the clinical interpretation of total B12 assays was collated from participants of the UK NEQAS for Haematinic Assays Scheme. From these data we characterised the geographical variation in diagnostic thresholds across the United Kingdom to identify regions with poor adherence to National Institute for Health and Care Excellence (NICE) guidance (NG239). Methods: Applied diagnostic thresholds for total B12 were collated from scheme participants and summarised. Because of the reported negative analytical bias of the Beckman DxI total B12 assay in comparison to total B12 assays from Abbott, Roche and Siemens, assay compatibility with NG239 was assessed by deriving a Beckman DxI-specific reference interval using an indirect Hoffman approach applied to 61,117 routine clinical samples. Results: Diagnostic thresholds for total B12 varied widely across the UK (65–239 ng/L; 48–176 pmol/L). Only 16.6 % of laboratories used the NG239 best-practice threshold of 180 ng/L (133 pmol/L). The Beckman DxI total B12 assay was not compatible with the NG239 cut-off; a lower threshold, such as a locally derived cut-off or the manufacturer’s recommended 145 ng/L (107 pmol/L), was indicated for this platform. Conclusions: Substantial national heterogeneity in applied total B12 diagnostic thresholds persist, with limited adoption of NG239 guidance. Platform-related analytical bias undermines the use of universal decision limits. For Beckman DxI, use of a platform-appropriate threshold is required to support clinically consistent diagnosis of vitamin B12 deficiency.
- 24 June 2026
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 64 (11) , 2389-2397
Unwarranted variation in total B12 test thresholds for the diagnosis of vitamin B12 deficiency across the UK and the validation of a method-specific total B12 reference interval for the Beckman Coulter DxI platform to support implementation of NICE NG239
Background: Prompt diagnosis and treatment of vitamin B12 deficiency prevents haematological, neurological, psychological and psychiatric disturbances. During November 2024, reference interval data used for the clinical interpretation of total B12 assays was collated from participants of the UK NEQAS for Haematinic Assays Scheme. From these data we characterised the geographical variation in diagnostic thresholds across the United Kingdom to identify regions with poor adherence to National Institute for Health and Care Excellence (NICE) guidance (NG239). Methods: Applied diagnostic thresholds for total B12 were collated from scheme participants and summarised. Because of the reported negative analytical bias of the Beckman DxI total B12 assay in comparison to total B12 assays from Abbott, Roche and Siemens, assay compatibility with NG239 was assessed by deriving a Beckman DxI-specific reference interval using an indirect Hoffman approach applied to 61,117 routine clinical samples. Results: Diagnostic thresholds for total B12 varied widely across the UK (65–239 ng/L; 48–176 pmol/L). Only 16.6 % of laboratories used the NG239 best-practice threshold of 180 ng/L (133 pmol/L). The Beckman DxI total B12 assay was not compatible with the NG239 cut-off; a lower threshold, such as a locally derived cut-off or the manufacturer’s recommended 145 ng/L (107 pmol/L), was indicated for this platform. Conclusions: Substantial national heterogeneity in applied total B12 diagnostic thresholds persist, with limited adoption of NG239 guidance. Platform-related analytical bias undermines the use of universal decision limits. For Beckman DxI, use of a platform-appropriate threshold is required to support clinically consistent diagnosis of vitamin B12 deficiency.
- Open Access
- 24 June 2026
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 64 (10) , e243-e245
Shift happens again: a call to action for EQA providers to rise to the post market surveillance challenge
- 24 June 2026
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 64 (10) , e243-e245
Open AccessShift happens again: a call to action for EQA providers to rise to the post market surveillance challenge
- Open Access
- 12 June 2026
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 64 (10) , 2159-2167
Clinical quality in UK laboratory medicine: current status and what the wider laboratory community can learn
In the UK, in 2024, variation in the performance of the HbA1c assay resulted in the misdiagnosis of patients. This was well publicised in the media, and over 55,000 patients (in England) needed to be recalled for repeat testing, and many patients had their diagnosis changed. However, during the investigation into this event, it became clear that the Clinical Quality Infrastructure for laboratory medicine in the UK requires review. The importance of such an infrastructure was first proposed in the Barnes Report into how diagnostic variation resulted in misdiagnosis of patients. During our review into the recent event, it became clear that little of the Ian Barnes recommendations have been translated into practice, and we discovered further ‘gaps’ in the laboratory medicine Quality Infrastructure that could be applicable to the wider laboratory community. This article will not focus specifically on the HbA1c incident but will use HbA1c as an example of what we have used for a springboard for change and gives an overview of key areas that clinical laboratories should be considering as part of their risk management for the services provided for patient care. A number of recommendations have been made for UK laboratories endorsed by GIRFT (Getting It Right First Time), Birmingham Quality (member of the UK NEQAS consortium) and Weqas.
- 12 June 2026
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 64 (10) , 2159-2167
Open AccessClinical quality in UK laboratory medicine: current status and what the wider laboratory community can learn
In the UK, in 2024, variation in the performance of the HbA1c assay resulted in the misdiagnosis of patients. This was well publicised in the media, and over 55,000 patients (in England) needed to be recalled for repeat testing, and many patients had their diagnosis changed. However, during the investigation into this event, it became clear that the Clinical Quality Infrastructure for laboratory medicine in the UK requires review. The importance of such an infrastructure was first proposed in the Barnes Report into how diagnostic variation resulted in misdiagnosis of patients. During our review into the recent event, it became clear that little of the Ian Barnes recommendations have been translated into practice, and we discovered further ‘gaps’ in the laboratory medicine Quality Infrastructure that could be applicable to the wider laboratory community. This article will not focus specifically on the HbA1c incident but will use HbA1c as an example of what we have used for a springboard for change and gives an overview of key areas that clinical laboratories should be considering as part of their risk management for the services provided for patient care. A number of recommendations have been made for UK laboratories endorsed by GIRFT (Getting It Right First Time), Birmingham Quality (member of the UK NEQAS consortium) and Weqas.
- Open Access
- 26 November 2025
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 64 (4) , e75-e78
Shift happens: the utility of external quality assessment data in evaluating folate lot changes
- 26 November 2025
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 64 (4) , e75-e78
Open AccessShift happens: the utility of external quality assessment data in evaluating folate lot changes
- 23 August 2025
- Published by SAGE Publications in Annals of Clinical Biochemistry: International Journal of Laboratory Medicine
- Vol. 63 (2) , 141-151
The missing piece: Who is responsible for ensuring clinical chemistry assays used in the UK are fit for purpose?
Over the past 50 years, External Quality Assessment (EQA) Schemes in the UK have changed from being overseen by the Department of Health and Social Security (DHSS) to a self-funding model post-1990, increasing competition among schemes. Despite reforms, there is no single source for assessing UK laboratories’ performance. Laboratories often use a single manufacturer, which can restrict laboratories to having to use a poor method for some assays. Regulatory changes like the EU In Vitro Diagnostics Regulation (IVDR) impact manufacturers. The Medicines & Healthcare products Regulatory Agency (MHRA) oversees assay performance, focusing on patient harm. Participation in EQA is mandatory for ISO 15189 accreditation, but the holistic quality of EQA services vary. Four cases studies (calcium, testosterone, paracetamol and total bilirubin) are presented that illustrate how the current systems are being used in practice. These show different elements of quality assurance, but crucially in all cases patient management will have been impacted. Most performance issues are manufacturer-related. EQA helps monitor assay quality, but gaps in oversight remain. Diagnostic reform is progressing, but differences in assay results pose risks. Laboratories must collaborate with stakeholders to ensure high-quality services. Mechanisms are needed to rectify sub-optimal assays. The current system can lead to patient misdiagnosis or incorrect clinical pathways. A mechanism is required to ensure accurate results for the public, within acceptable error margins, and at a sustainable cost for the NHS.
- 23 August 2025
- Published by SAGE Publications in Annals of Clinical Biochemistry: International Journal of Laboratory Medicine
- Vol. 63 (2) , 141-151
The missing piece: Who is responsible for ensuring clinical chemistry assays used in the UK are fit for purpose?
Over the past 50 years, External Quality Assessment (EQA) Schemes in the UK have changed from being overseen by the Department of Health and Social Security (DHSS) to a self-funding model post-1990, increasing competition among schemes. Despite reforms, there is no single source for assessing UK laboratories’ performance. Laboratories often use a single manufacturer, which can restrict laboratories to having to use a poor method for some assays. Regulatory changes like the EU In Vitro Diagnostics Regulation (IVDR) impact manufacturers. The Medicines & Healthcare products Regulatory Agency (MHRA) oversees assay performance, focusing on patient harm. Participation in EQA is mandatory for ISO 15189 accreditation, but the holistic quality of EQA services vary. Four cases studies (calcium, testosterone, paracetamol and total bilirubin) are presented that illustrate how the current systems are being used in practice. These show different elements of quality assurance, but crucially in all cases patient management will have been impacted. Most performance issues are manufacturer-related. EQA helps monitor assay quality, but gaps in oversight remain. Diagnostic reform is progressing, but differences in assay results pose risks. Laboratories must collaborate with stakeholders to ensure high-quality services. Mechanisms are needed to rectify sub-optimal assays. The current system can lead to patient misdiagnosis or incorrect clinical pathways. A mechanism is required to ensure accurate results for the public, within acceptable error margins, and at a sustainable cost for the NHS.
- 11 December 2024
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 63 (5) , 841-843
Are the benefits of External Quality Assessment (EQA) recognized beyond the echo chamber?
Article Are the benefits of External Quality Assessment (EQA) recognized beyond the echo chamber? was published on January 13, 2025 in the journal Clinical Chemistry and Laboratory Medicine (CCLM) (volume 0, issue 0).
- 11 December 2024
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 63 (5) , 841-843
Are the benefits of External Quality Assessment (EQA) recognized beyond the echo chamber?
Article Are the benefits of External Quality Assessment (EQA) recognized beyond the echo chamber? was published on January 13, 2025 in the journal Clinical Chemistry and Laboratory Medicine (CCLM) (volume 0, issue 0).
- Open Access
- 4 April 2024
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 62 (9) , 1824-1834
Understanding the limitations of your assay using EQA data with serum creatinine as an example
Objectives: Laboratories need to take into consideration the specificity and imprecision of assays not only in verification, but also of quality assessment. This study investigates the composition of serum used in EQA materials by comparing material from a single and multiple donors (pooled material), across multiple methods, using creatinine as an example. Methods: Sixteen different serum matrices were distributed as 36 specimens through the UK NEQAS for Acute and Chronic Kidney Disease Scheme from March 2022 to March 2023. Male-only and female-only serum was used as single donations, pooled donations, unmanipulated or with added exogenous creatinine. Specimens were distributed to primarily UK participants (approximately n=500) for creatinine analysis. Data has been reviewed by method compared to the enzymatic creatinine method principle mean. Results: From the 16 different matrices, only the enzymatic creatinine assay systems from Roche Cobas and Siemens Atellica met the minimum acceptable bias goal, from biological data, of 5.6 %, in all specimens. Pooled material showed less variation in bias across all methods. Conclusions: Since Laboratories invest a lot of time and money in quality management, they need to know the limitations of their assays so that they are not investigating ‘apparent’ EQA/IQC problems which are purely due to non-specific, imprecise assay, rather than an analytical issue in their laboratory. When large numbers of individual donations are combined, interferents are essentially diluted out. Therefore, if EQA material is of this type it will be very difficult to determine the actual assay’s bias and variability.
- 4 April 2024
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 62 (9) , 1824-1834
Open AccessUnderstanding the limitations of your assay using EQA data with serum creatinine as an example
Objectives: Laboratories need to take into consideration the specificity and imprecision of assays not only in verification, but also of quality assessment. This study investigates the composition of serum used in EQA materials by comparing material from a single and multiple donors (pooled material), across multiple methods, using creatinine as an example. Methods: Sixteen different serum matrices were distributed as 36 specimens through the UK NEQAS for Acute and Chronic Kidney Disease Scheme from March 2022 to March 2023. Male-only and female-only serum was used as single donations, pooled donations, unmanipulated or with added exogenous creatinine. Specimens were distributed to primarily UK participants (approximately n=500) for creatinine analysis. Data has been reviewed by method compared to the enzymatic creatinine method principle mean. Results: From the 16 different matrices, only the enzymatic creatinine assay systems from Roche Cobas and Siemens Atellica met the minimum acceptable bias goal, from biological data, of 5.6 %, in all specimens. Pooled material showed less variation in bias across all methods. Conclusions: Since Laboratories invest a lot of time and money in quality management, they need to know the limitations of their assays so that they are not investigating ‘apparent’ EQA/IQC problems which are purely due to non-specific, imprecise assay, rather than an analytical issue in their laboratory. When large numbers of individual donations are combined, interferents are essentially diluted out. Therefore, if EQA material is of this type it will be very difficult to determine the actual assay’s bias and variability.
- Open Access
- 22 March 2024
- Published by Springer Nature in Accreditation and Quality Assurance
- Vol. 29 (5-6) , 333-343
Comparisons of real versus synthetic proficiency testing items
Both real and synthetic materials are regularly used by providers of external quality assessment and proficiency testing schemes, and there are, in most cases, justifiable reasons for the choice made. This article focusses on the field of clinical biochemistry and discusses the different properties of a material and the benefits and limitations of using real or synthetic material. However, the overarching principles should be able to be applied to all sectors within the laboratory. Whilst genuine/real material would appear to be the preferred matrix, this is not always practicable, and synthetic material may be a suitable alternative. Synthetic material covers a wide range of material, be it that the material is 100% artificial to real material being used as a ‘base’ item, which is manipulated either by the addition of further real material from a different source or by the addition of exogenous analyte. A number of real-life cases are presented to demonstrate the impact of material matrix, storage conditions, volume, and interferences.
- 22 March 2024
- Published by Springer Nature in Accreditation and Quality Assurance
- Vol. 29 (5-6) , 333-343
Open AccessComparisons of real versus synthetic proficiency testing items
Both real and synthetic materials are regularly used by providers of external quality assessment and proficiency testing schemes, and there are, in most cases, justifiable reasons for the choice made. This article focusses on the field of clinical biochemistry and discusses the different properties of a material and the benefits and limitations of using real or synthetic material. However, the overarching principles should be able to be applied to all sectors within the laboratory. Whilst genuine/real material would appear to be the preferred matrix, this is not always practicable, and synthetic material may be a suitable alternative. Synthetic material covers a wide range of material, be it that the material is 100% artificial to real material being used as a ‘base’ item, which is manipulated either by the addition of further real material from a different source or by the addition of exogenous analyte. A number of real-life cases are presented to demonstrate the impact of material matrix, storage conditions, volume, and interferences.